LncRNA ITGB2-AS1 Promotes the Progression of Clear Cell Renal Cell Carcinoma by Modulating MiR-328-5p/HMGA1 Axis

Overview

Journal Hum Cell

Publisher Springer

Specialty Cell Biology

Date 2021 Jun 25

PMID 34170494

Citations 10

Authors

Wensheng Zhang

Yigang Lu

Huibo Shi

Xungang Li

Zhuo Zhang

Xinxi Deng

Yang Yang

Bin Wan

Affiliations

Soon will be listed here.

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common histologic subtype of renal cell carcinoma and long non-coding RNAs (lncRNAs) play important roles in the progression of ccRCC. In this study, we aim to explore the potential function of ITGB2-AS1 in ccRCC progression and its underlying molecular mechanism. We first explored the association between ITGB2-AS1 expression level and ccRCC prognosis. We found that the expression level of ITGB2-AS1 was significantly higher in ccRCC tumor and cell lines, and highly expressed ITGB2-AS1 was also associated with a poorer prognosis. Consistently, silencing ITGB2-AS1 inhibited proliferation, promoted apoptosis in ccRCC cell lines, and curbed the tumorigenesis in the Xenograft model, reduced tumorigenesis in a xenograft tumor growth model. We further identified and confirmed the miRNA miR-328-5p as a target of ITGB2-AS1, and miR-328-5p negatively regulated the expression of HMGA1 protein. The anti-tumor effect of silencing ITGB2-AS1 could be partially rescued by inhibiting miR-328-5p activity or overexpressing HMGA1, indicating that ITGB2-AS1 promotes the survival and progression of ccRCC by modulating miR-328-5p/HMGA1 axis. Collectively, our data demonstrated that ITGB2-AS1 expression level is positively correlated with the survival and tumorigenesis of ccRCC. As a target of ITGB2-AS1, miR-328-5p seems to function as a tumor-suppressor, and the oncogenic effect of ITGB2-AS1 is partially mediated via the miR-328-5p/HMGA1 axis.

Citing Articles

Complicated crosstalk between HMGA and non-coding RNAs modulates hallmarks of cancer.

Zhang L, Zhao X, Gao X, Qin H, Chen F, Lin Z Cancer Cell Int. 2025; 25(1):80.

PMID: 40055693 PMC: 11887209. DOI: 10.1186/s12935-025-03713-1.

Evidence for a Role of the Long Non-Coding RNA ITGB2-AS1 in Eosinophil Differentiation and Functions.

Fettrelet T, Hosseini A, Wyss J, Boros-Majewska J, Stojkov D, Yousefi S Cells. 2024; 13(23).

PMID: 39682685 PMC: 11640120. DOI: 10.3390/cells13231936.

Serum lncRNA ITGB2-AS1 and ICAM-1 as novel biomarkers for rheumatoid arthritis and osteoarthritis diagnosis.

Selim A, Elsabagh Y, El-Sawalhi M, Ismail N, Senousy M BMC Med Genomics. 2024; 17(1):247.

PMID: 39379962 PMC: 11462822. DOI: 10.1186/s12920-024-01993-6.

LncRNA ITGB2-AS1 promotes cisplatin resistance of non-small cell lung cancer by inhibiting ferroptosis via activating the FOSL2/NAMPT axis.

Chen H, Wang L, Liu J, Wan Z, Zhou L, Liao H Cancer Biol Ther. 2023; 24(1):2223377.

PMID: 37370246 PMC: 10308868. DOI: 10.1080/15384047.2023.2223377.

A review on the role of long non-coding RNA and microRNA network in clear cell renal cell carcinoma and its tumor microenvironment.

Zhang Q, Ren H, Ge L, Zhang W, Song F, Huang P Cancer Cell Int. 2023; 23(1):16.

PMID: 36732762 PMC: 9893571. DOI: 10.1186/s12935-023-02861-6.

References

Gupta K, Miller J, Li J, Russell M, Charbonneau C . Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008; 34(3):193-205. DOI: 10.1016/j.ctrv.2007.12.001. View

Kim S, Park B, Hwang E, Hong S, Jeong C, Kwak C . Retrospective Multicenter Long-Term Follow-up Analysis of Prognostic Risk Factors for Recurrence-Free, Metastasis-Free, Cancer-Specific, and Overall Survival After Curative Nephrectomy in Non-metastatic Renal Cell Carcinoma. Front Oncol. 2019; 9:859. PMC: 6738012. DOI: 10.3389/fonc.2019.00859. View

Jonasch E, Gao J, Rathmell W . Renal cell carcinoma. BMJ. 2014; 349:g4797. PMC: 4707715. DOI: 10.1136/bmj.g4797. View

Yu G, Yao W, Wang J, Ma X, Xiao W, Li H . LncRNAs expression signatures of renal clear cell carcinoma revealed by microarray. PLoS One. 2012; 7(8):e42377. PMC: 3412851. DOI: 10.1371/journal.pone.0042377. View

Schmitt A, Chang H . Long Noncoding RNAs in Cancer Pathways. Cancer Cell. 2016; 29(4):452-463. PMC: 4831138. DOI: 10.1016/j.ccell.2016.03.010. View

Zhan Y, Chen Z, Li Y, He A, He S, Gong Y . Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA. J Exp Clin Cancer Res. 2018; 37(1):273. PMC: 6233575. DOI: 10.1186/s13046-018-0921-1. View

Chen D, Lu Y, Zhang J, Wei X, Wang F, Zeng Z . Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression. Theranostics. 2017; 7(19):4836-4849. PMC: 5706103. DOI: 10.7150/thno.20942. View

Zhou C, Liu H, Wang F, Hu T, Liang Z, Lan N . circCAMSAP1 Promotes Tumor Growth in Colorectal Cancer via the miR-328-5p/E2F1 Axis. Mol Ther. 2020; 28(3):914-928. PMC: 7054739. DOI: 10.1016/j.ymthe.2019.12.008. View

Liu Z, Yu Y, Huang Z, Kong Y, Hu X, Xiao W . CircRNA-5692 inhibits the progression of hepatocellular carcinoma by sponging miR-328-5p to enhance DAB2IP expression. Cell Death Dis. 2019; 10(12):900. PMC: 6881381. DOI: 10.1038/s41419-019-2089-9. View

10.

Luo T, Yan Y, He Q, Ma X, Wang W . miR-328-5p inhibits MDA-MB-231 breast cancer cell proliferation by targeting RAGE. Oncol Rep. 2018; 39(6):2906-2914. DOI: 10.3892/or.2018.6353. View

11.

Dong H, Sun S, Yan T, Liang C, Zhu J, Miao C . MicroRNA-195 inhibits proliferation and metastasis in renal cell carcinoma via regulating HMGA1. Am J Transl Res. 2020; 12(6):2781-2792. PMC: 7344069. View

12.

Martens-Uzunova E, Bottcher R, Croce C, Jenster G, Visakorpi T, Calin G . Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2013; 65(6):1140-51. DOI: 10.1016/j.eururo.2013.12.003. View

13.

Qu L, Wang Z, Chen Q, Li Y, He H, Hsieh J . Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. Eur Urol. 2018; 74(6):756-763. DOI: 10.1016/j.eururo.2018.07.032. View

14.

Duan J, Ma X, Shi J, Xuan Y, Wang H, Li P . Long noncoding RNA promotes proliferation through EZH2 and predicts poor prognosis in clear cell renal cell carcinoma. Onco Targets Ther. 2019; 12:4729-4740. PMC: 6592040. DOI: 10.2147/OTT.S202938. View

15.

Abak A, Amini S, Sakhinia E, Abhari A . MicroRNA-221: biogenesis, function and signatures in human cancers. Eur Rev Med Pharmacol Sci. 2018; 22(10):3094-3117. DOI: 10.26355/eurrev_201805_15069. View

16.

Sun C, Li S, Yuan Z, Li D . MicroRNA-346 facilitates cell growth and metastasis, and suppresses cell apoptosis in human non-small cell lung cancer by regulation of XPC/ERK/Snail/E-cadherin pathway. Aging (Albany NY). 2016; 8(10):2509-2524. PMC: 5115903. DOI: 10.18632/aging.101080. View

17.

Sun C, Li S, Zhang F, Zhang Y, Zuo Z, Xi Y . The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non-small-cell Lung Cancer Through Altering STAT3 Expression. Mol Ther Nucleic Acids. 2016; 5(11):e387. PMC: 5155328. DOI: 10.1038/mtna.2016.96. View

18.

Huang R, Huang D, Dai W, Yang F . Overexpression of HMGA1 correlates with the malignant status and prognosis of breast cancer. Mol Cell Biochem. 2015; 404(1-2):251-7. DOI: 10.1007/s11010-015-2384-4. View

19.

Kettunen E, Anttila S, Seppanen J, Karjalainen A, Edgren H, Lindstrom I . Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet. 2004; 149(2):98-106. DOI: 10.1016/S0165-4608(03)00300-5. View

20.

Balcerczak M, Pasz-Walczak G, Balcerczak E, Wojtylak M, Kordek R, Mirowski M . HMGI(Y) gene expression in colorectal cancer: comparison with some histological typing, grading, and clinical staging. Pathol Res Pract. 2003; 199(10):641-6. DOI: 10.1078/0344-0338-00475. View